The latest official response: who should be vaccinated first and whether there are adverse reactions?

category:Health
 The latest official response: who should be vaccinated first and whether there are adverse reactions?


Four of them entered phase III clinical trials

It is understood that Chinas vaccine research and development work is generally in a leading position. There are vaccines entering the clinical research stage in each technical route, and 13 vaccines have entered clinical trials. Among them, inactivated vaccine and adenovirus vector vaccine two technical routes, a total of 4 vaccines have entered phase III clinical trial. The four vaccines that entered the phase III clinical trial stage, on the whole, have progressed smoothly. Up to now, about 60000 subjects have been vaccinated with inactivated vaccines.

Who can give priority to vaccination?

According to the vaccine management law, in the event of a particularly serious public health event, the national health and Health Commission shall submit an application for emergency use of vaccine. The State Food and drug administration shall organize experts to demonstrate and agree, and the national health and Health Commission shall use the vaccine within a certain range and within a certain time limit.

Zheng Zhongwei, head of the vaccine research and development team of the scientific research team and director of the science and technology development center of the National Health Commission, said that the future vaccination population of the new coronavirus can be roughly divided into three categories: high-risk groups, high-risk groups and ordinary people.

The high-risk population mainly refers to the front-line medical and epidemic prevention personnel, border and port staff, as well as staff who have to go to high-risk areas or countries due to work reasons, as well as some staff who want to ensure the basic operation of the city. High risk groups mainly refer to the elderly, children, pregnant women and people with basic diseases. Once infected with the new crown, the proportion of patients with severe or critical illness is far greater than that of other groups. Therefore, these two groups of people should be considered as priority vaccination.

Are there any serious adverse reactions?

Liu Jingzhen, chairman and Secretary of the Party committee of sinopharma group, said that two kinds of inactivated vaccines from Beijing Institute of biological products and Wuhan Institute of biological products, affiliated to Sinopharm group, are now conducting phase III clinical trials in ten countries, including the United Arab Emirates, France, Jordan, Peru, Argentina and Egypt. At present, more than 50000 people have been vaccinated, and the sample size of vaccination population covers 125 countries A total of 60000 people will be vaccinated.

At present, dozens of countries have put forward the demand of new crown vaccine to Sinopharm Group China biology. Sinopharma groups research and development of biological vaccine in China is the last kilometer of a long march. After the safety and protection data of phase III clinical trial are obtained, the vaccine can be put on the market after being approved by the evaluation Liu Jingzhen said that so far, China biology has not received and observed serious adverse reactions, and the safety response is good.

In fact, the two inactivated vaccines of sinopharma Group China biology have been included in the scope of emergency use in China. Liu Jingzhen said that at present, Chinas biology has made preparations for large-scale production. Two new crown vaccine high-level biosafety production workshops of Beijing Institute of biological products and Wuhan Institute of biological products have been completed. The production capacity will reach more than 1 billion doses next year, which can ensure the safe and sufficient vaccine supply.

Is the emergency use of vaccine rash?

Zheng Zhongwei responded that China is faced with huge pressure of importing new coronal vaccine. Heilongjiang, Beijing, Xinjiang, Dalian and Qingdao have successively had small-scale clustering outbreaks, which shows that the pressure of domestic epidemic rebound is still huge. For people who are always exposed to high risk in the process of anti epidemic, it is very necessary to carry out emergency use of vaccine to protect their life, health and safety.

Zheng Zhongwei stressed that the initiation of emergency use has been strictly demonstrated and reviewed, and it also meets the relevant rules of the World Health Organization. After the approval of the emergency use of the new crown vaccine in China, we also communicated with the representative office of the World Health Organization in China, and obtained their recognition and support. In the process of promoting the emergency use of new crown vaccine, a very strict expert demonstration was carried out. The leader of the expert group was academician Zhong Nanshan, and the Deputy group leader was Academician Wang Junzhi. The members of the expert group also included a group of domestic high-level and authoritative legal experts, ethical experts and clinical experts.

Zheng Zhongwei also said that emergency use was organized and implemented on the premise of voluntary, informed and consent, and established a very strict screening of audience personnel, monitoring of adverse reactions and emergency treatment, as well as a follow-up work program after vaccination. So far, no serious adverse reactions have been reported in all personnel carrying out emergency use of the new crown vaccine in China, and no infection has been reported in some people working in high-risk areas. Zheng Zhongwei also said that it is expected that by the end of this year, Chinas annual production capacity of the new crown vaccine will reach 610 million doses. Next year, the annual production capacity of Chinas new crown vaccine will be effectively expanded on this basis, so as to ensure the demand for Chinas new crown vaccine and other countries in the world. Netease health will also pay attention to every footprint of the new crown vaccine research and development together with you. Is the side effect of antidepressants a great flood? Sudden death happens frequently. Why do hundreds of millions of people not know the AED? Is the epidemic over? Can we go out on National Day? Source: Netease health editor: Wu Yanli_ Nbjs6202 this article is an original manuscript of Netease. The copyright belongs to NetEase. It is not allowed to reprint without authorization. When downloading and using the media authorized by agreement, the source of the manuscript must be indicated: Netease. Violators will be held responsible according to law. .ep-statement{ clear:both;float :left;line- height:2;font :12px/22pxSimsun;color:#888;margin- top:10px;

Zheng Zhongwei also said that emergency use was organized and implemented on the premise of voluntary, informed and consent, and established a very strict screening of audience personnel, monitoring of adverse reactions and emergency treatment, as well as a follow-up work program after vaccination. So far, no serious adverse reactions have been reported in all personnel carrying out emergency use of the new crown vaccine in China, and no infection has been reported in some people working in high-risk areas.

Zheng Zhongwei also said that it is expected that by the end of this year, Chinas annual production capacity of the new crown vaccine will reach 610 million doses. Next year, the annual production capacity of Chinas new crown vaccine will be effectively expanded on this basis, so as to ensure the demand for Chinas new crown vaccine and other countries in the world. Netease health will also pay attention to every footprint of the new crown vaccine research and development together with you.